Cited by 396Breast Cancer Treatment StudiesEstrogen and related hormone effectsAdvanced Breast Cancer Therapies

The DOI matches its Crossref record, with a small difference in title or year; 61 of the 61 references it cites were found in a registry or an index.

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer: A Systematic Review and Meta-analysis

Open access

Spring, Laura M., Gupta, Arjun, Reynolds, Kerry L., Gadd, Michele A., Ellisen, Leif W., Isakoff, Steven J., Moy, Beverly, Bardia, Aditya·2016·JAMA Oncology

DOI 10.1001/jamaoncol.2016.1897PMC PMC5738656

Open this paper in CoChat — free account

Abstract

IMPORTANCE: Estrogen receptor-positive (ER+) tumors of the breast are generally highly responsive to endocrine treatment. Although endocrine therapy is the mainstay of adjuvant treatment for ER+ breast cancer, the role of endocrine therapy in the neoadjuvant setting is unclear. OBJECTIVE: To evaluate the effect of neoadjuvant endocrine therapy (NET) on the response rate and the rate of breast conservation surgery (BCS) for ER+ breast cancer. DATA SOURCES: Based on PRISMA guidelines, a librarian-led search of PubMed and Ovid MEDLINE was performed to identify eligible trials published from inception to May 15, 2015. The search was performed in May 2015. STUDY SELECTION: Inclusion criteria were prospective, randomized, neoadjuvant clinical trials that reported response rates with at least 1 arm incorporating NET (n = 20). Two authors independently analyzed the studies for inclusion. DATA EXTRACTION AND SYNTHESIS: Pooled odds ratios (ORs), 95% CIs, and P values were estimated for end points using the fixed- and random-effects statistical model. RESULTS: The analysis included 20 studies with 3490 unique patients. Compared with combination chemotherapy, NET as monotherapy with aromatase inhibitors had a similar clinical response rate (OR, 1.08; 95% CI, 0.50-2.35; P = .85; n = 378), radiological response rate (OR, 1.38; 95% CI, 0.92-2.07; P = .12; n = 378), and BCS rate (OR, 0.65; 95% CI, 0.41-1.03; P = .07; n = 334) but with lower toxicity. Aromatase inhibitors were associated with a significantly higher clinical response rate (OR, 1.69; 95% CI, 1.36-2.10; P < .001; n = 1352), radiological response rate (OR, 1.49; 95% CI, 1.18-1.89; P < .001; n = 1418), and BCS rate (OR, 1.62; 95% CI, 1.24-2.12; P < .001; n = 918) compared with tamoxifen. Dual combination therapy with growth factor pathway inhibitors was associated with a higher radiological response rate (OR, 1.59; 95% CI, 1.04-2.43; P = .03; n = 355), but not clinical response rate (OR, 0.76; 95% CI, 0.54-1.07; P = .11; n = 537), compared with endocrine monotherapy. The incidence of pathologic complete response was low (<10%). CONCLUSIONS AND RELEVANCE: Neoadjuvant endocrine therapy, even as monotherapy, is associated with similar response rates as neoadjuvant combination chemotherapy but with significantly lower toxicity, suggesting that NET needs to be reconsidered as a potential option in the appropriate setting. Additional research is needed to develop rational NET combinations and predictive biomarkers to personalize the optimal neoadjuvant strategy for ER+ breast cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2016.1897

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010) · International Journal of Surgery · doi:10.1016/j.ijsu.2010.02.007 · Cited by 12,156
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2014) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,609
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Cortazar, P., Zhang, L., Untch, M., Mehta, K. M., Costantino, J. P., Wolmark, N., Bonnefoi, H. R., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,777
Efficacy and Safety of Tadalafil Monotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Meta-Analysis
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,557
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900

Show all 60 references

Research works printed but not linked: 1

[61]Ma CX Gao F Northfelt D A phase II trial of neoadjuvant palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen receptor positive HER2 negative (ER+HER2−) breast cancer (BC) Presented at: San Antonio Breast Cancer Symposium December 11, 2015 San Antonio, TX Abstract S6-05

Sorted by citations

Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline update
Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chavez-MacGregor, M., Perlmutter, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02309 · Cited by 1,574
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Korde, L. A., Somerfield, M. R., Carey, L., Crews, J. R., Denduluri, N., Hwang, E. S., Khan, S. A., Loibl, S., Morris, E. A., Perez, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03399 · Cited by 1,056
Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium
Dietz, J. R., Moran, M. S., Isakoff, S. J., Kurtzman, S. H., Willey, S. C., Burstein, H. J., Bleicher, R. J., Lyons, J. A., Sarantou, T., Baron, P. L., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05644-z · Cited by 392
Self-citation
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update
Allison, K. H., Hammond, M. E., Dowsett, M., McKernin, S. E., Carey, L., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chávez‐MacGregor, M., Perlmutter, J., et al. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0904-sa · Cited by 392
Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
Burstein, H. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1307118 · Cited by 316
Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG)
Biganzoli, L., Battisti, N. M. L., Wildiers, H. P. M. W., McCartney, A., Colloca, G. A., Kunkler, I. H., Cardoso, M. J., Cheung, K., de Glas, N. A., Trimboli, R. M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30741-5 · Cited by 307
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial
Johnston, S. R. D., Puhalla, S., Wheatley, D. A., Ring, A. E., Barry, P. A., Holcombe, C., Boileau, J. F., Provencher, L., Robidoux, A., Rimawi, M. F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01624 · Cited by 228
Efficacy of PI3K inhibitors in advanced breast cancer
Verret, B., Cortes, J., Bachelot, T., Andre, F., & Arnedos, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz381 · Cited by 221
Assessment of Time-to-Treatment Initiation and Survival in a Cohort of Patients With Common Cancers
Cone, E. B., Marchese, M., Paciotti, M., Nguyen, D., Nabi, J., Cole, A. P., Molina, G., Molina, R. L., Minami, C. A., Mucci, L. A., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.30072 · Cited by 210
Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies
Carvalho, M. E. S., Canberk, Ş., Schmitt, F. C., & Vale, N. (2025) · Cancers · doi:10.3390/cancers17071102 · Cited by 176
Resistance and Overcoming Resistance in Breast Cancer
Luque-Bolivar, A., Pérez-Mora, E., Villegas, V. E., & Rondón‐Lagos, M. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s270799 · Cited by 139
Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice
Cain, H. J., Macpherson, I. R., Beresford, M. J., Pinder, S. E., Pong, J. Z., & Dixon, J. M. (2017) · Clinical Oncology · doi:10.1016/j.clon.2017.06.003 · Cited by 126
Vorinostat (SAHA) and Breast Cancer: An Overview
Wawruszak, A., Borkiewicz, L., Okoń, E., Kukuła‐Koch, W., Afshan, S., & Hałasa, M. (2021) · Cancers · doi:10.3390/cancers13184700 · Cited by 124
A systematic review and meta-analysis of surgery delays and survival in breast, lung and colon cancers: Implication for surgical triage during the COVID-19 pandemic
Johnson, B. A., Waddimba, A. C., Ogola, G., Fleshman, J. W., & Preskitt, J. T. (2020) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2020.12.015 · Cited by 122
Are all cyclin-dependent kinases 4/6 inhibitors created equal?
Marra, A., & Curigliano, G. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0121-y · Cited by 120
Rethinking neoadjuvant chemotherapy for breast cancer
Vaidya, J. S., Massarut, S., Vaidya, H. J., Alexander, E. C., Richards, T., Caris, J. A., Sirohi, B., & Tobias, J. S. (2018) · BMJ · doi:10.1136/bmj.j5913 · Cited by 109
Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study
Iwata, H., Masuda, N., Yamamoto, Y., Fujisawa, T., Toyama, T., Kashiwaba, M., Ohtani, S., Taira, N., Sakai, T., Hasegawa, Y., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4964-y · Cited by 101
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Mayer, I. A., Prat, A., Egle, D., Blau, S. H., Fidalgo, J. A. P., Gnant, M., Fasching, P. A., Colleoni, M. A., Wolff, A. C., Winer, E. P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3160 · Cited by 100
Recent strategies to overcome breast cancer resistance
Khan, M. M., Yalamarty, S. S. K., Rajmalani, B. A., Filipczak, N., & Torchilin, V. P. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104351 · Cited by 100
Using the 21‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial
Bear, H. D., Wan, W., Robidoux, A., Rubin, P., Limentani, S. A., White, R. L., Granfortuna, J. M., Hopkins, J. O., Oldham, D. S., Rodriguez, A. A., et al. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24610 · Cited by 96
Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group
Battisti, N. M. L., Mislang, A. R., Cooper, L., O'Donovan, A., Audisio, R. A., Cheung, K.-L., Sarrió, R. G., Stauder, R., Soto-Perez-de-Celis, E., Jaklitsch, M., et al. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.07.008 · Cited by 79
“A neoadjuvant endocrine approach is particularly valuable for older patients with estrogen receptorpositive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, as aromatase inhibitors are associated with low toxicity and reasonable response rates at 3–4months [92].”
Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine
Wu, Y., Liu, Z., & Xu, X. (2020) · 癌症：英文版 · doi:10.1002/cac2.12115 · Cited by 79
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
Barchiesi, G., Mazzotta, M., Krasniqi, E., Pizzuti, L., Marinelli, D., Capomolla, E. M., Sergi, D., Amodio, A., Natoli, C., Gamucci, T., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103528 · Cited by 80
The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer
Spring, L. M., Bar, Y., & Isakoff, S. J. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7016 · Cited by 83
Self-citation
Biomarkers and Imaging of Breast Cancer
Weaver, O. O., & Leung, J. W. T. (2017) · American Journal of Roentgenology · doi:10.2214/ajr.17.18708 · Cited by 77
Tumor Response After Neoadjuvant Magnetic Resonance Guided Single Ablative Dose Partial Breast Irradiation
Vasmel, J. E., Charaghvandi, R. K., Houweling, A. C., Philippens, M. E. P., van Asselen, B., Vreuls, C. P. H., van Diest, P. J., van Leeuwen, A. M. G., van Gorp, J., Witkamp, A. J., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.11.406 · Cited by 72
Recent Advances in the Neoadjuvant Treatment of Breast Cancer
Rubovszky, G., & Horváth, Z. (2017) · Journal of Breast Cancer · doi:10.4048/jbc.2017.20.2.119 · Cited by 68
Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity
Zhang, J., Lu, C.-Y., Chen, H., & Wu, S. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.1785 · Cited by 67
Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach
Sheng, J. Y.-S., Santa-Maria, C. A., Mangini, N. S., Norman, H., Couzi, R. J., Nunes, R., Wilkinson, M. J., Visvanathan, K., Connolly, R. M., Torres, E. T. R., et al. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00364 · Cited by 66
PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer
Yamamoto, T., Hayashida, T., Masugi, Y., Oshikawa, K., Hayakawa, N., Itoh, M., Nishime, C., Suzuki, M., Nagayama, A., Kawai, Y., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2266 · Cited by 60
Insight into the molecular evidence supporting the remarkable chemotherapeutic potential of Hibiscus sabdariffa L.
Laskar, Y. B., & Mazumder, P. B. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110153 · Cited by 59
Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
Andrahennadi, S., Sami, A., Manna, M., Pauls, M., & Ahmed, S. (2021) · Current Oncology · doi:10.3390/curroncol28030168 · Cited by 60
Neoadjuvant Endocrine Therapy in Clinical Practice
Sella, T., Weiss, A. C., Mittendorf, E. A., King, T. A., Pilewskie, M. L., Giuliano, A. E., & Metzger, O. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2132 · Cited by 59
Progesterone receptor membrane component 1 promotes the growth of breast cancers by altering the phosphoproteome and augmenting EGFR/PI3K/AKT signalling
Pedroza, D. A., Rajamanickam, V., Subramani, R., Bencomo, A., Galvez, A., & Lakshmanaswamy, R. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0992-6 · Cited by 58
Care Delivery Impact of the COVID-19 Pandemic on Breast Cancer Care
Satish, T., Raghunathan, R. R., Prigoff, J. G., Wright, J. D., Hillyer, G. C., Trivedi, M. S., Kalinsky, K. M., Crew, K. D., Hershman, D. L., & Accordino, M. K. (2021) · JCO Oncology Practice · doi:10.1200/op.20.01062 · Cited by 55
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
Cantini, L., Trapani, D., Guidi, L., Bielo, L. B., Scafetta, R., Koziej, M., Vidal, L., Saini, K. S., & Curigliano, G. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102669 · Cited by 60
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies
Steenbruggen, T. G., van Ramshorst, M. S., Kok, M., Linn, S. C., Smorenburg, C. H., & Sonke, G. S. (2017) · Drugs · doi:10.1007/s40265-017-0774-5 · Cited by 57
Management of hormone receptor-positive, HER2-negative early breast cancer
Walsh, E. M., Smith, K. L., & Stearns, V. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.05.010 · Cited by 57
Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer
Oshi, M., Tokumaru, Y., Angarita, F. A., Yan, L., Matsuyama, R., Endo, I., & Takabe, K. (2020) · Cancers · doi:10.3390/cancers12123557 · Cited by 53
Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer
de Inda, M. A., Blok, E. J., Kuppen, P. J. K., Charehbili, A., den Biezen, E., van Brussel, A., Fruytier, S. E., Kranenbarg, E. M., Kloet, S. L., van der Burg, B., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0318 · Cited by 53
How Effective is Neoadjuvant Endocrine Therapy (NET) in Downstaging the Axilla and Achieving Breast-Conserving Surgery?
Montagna, G., Sevilimedu, V., Fornier, M. N., Jhaveri, K. L., Morrow, M., & Pilewskie, M. L. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08888-7 · Cited by 53
Treatment Response Prediction Using Ultrasound-Based Pre-, Post-Early, and Delta Radiomics in Neoadjuvant Chemotherapy in Breast Cancer
Yang, M., Liu, H., Dai, Q., Yao, L., Zhang, S., Wang, Z., Li, J., & Duan, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.748008 · Cited by 52
Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery
Zotano, Á. G., & Arteaga, C. L. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0228 · Cited by 49
Pretreatment Tattoo Marking of Suspicious Axillary Lymph Nodes: Reliability and Correlation with Sentinel Lymph Node
Patel, R., MacKerricher, W. S., Tsai, J., Choy, N., Lipson, J. A., Ikeda, D. M., Pal, S., Martini, W. D., Allison, K. H., & Wapnir, I. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07419-3 · Cited by 49
Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory
AlOmeir, O., Patel, N., & Donyai, P. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05585-9 · Cited by 46
Hibiscus sabdariffa anthocyanins are potential modulators of estrogen receptor alpha activity with favourable toxicology: a computational analysis using molecular docking, ADME/Tox prediction, 2D/3D QSAR and molecular dynamics simulation
Laskar, Y. B., Laskar, M. A., Mazumder, P. B., & Talukdar, A. D. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.2009914 · Cited by 49
The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances
Khorasani, A. B. S., Hafezi, N., Sanaei, M., Jafari‐Raddani, F., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3998 · Cited by 47
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
Hurvitz, S. A., Bardia, A., Quiroga, V., Park, Y. H., Blancas, I., Alonso-Romero, J. L., Vasiliev, A., Adamchuk, H., Salgado, M., Yardley, D. A., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00268-1 · Cited by 46
Self-citation
Breast cancer management in 2021: A primer for the obstetrics and gynecology
Fleege, N. M. G., & Cobain, E. F. (2022) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2022.02.004 · Cited by 45
The Aging Skeleton
Goltzman, D. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-22254-3_12 · Cited by 45
Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: A systematic review and meta-analysis
Davey, M. G., Ryan, É. J., Boland, M. R., Barry, M. K., Lowery, A., & Kerin, M. J. (2021) · The Breast · doi:10.1016/j.breast.2021.04.010 · Cited by 43
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications
Griguolo, G., Bottosso, M., Vernaci, G. M., Miglietta, F., Dieci, M. V., & Guarneri, V. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102323 · Cited by 43
Meta-analysis of neoadjuvant therapy and its impact in facilitating breast conservation in operable breast cancer
Karakatsanis, A., Tasoulis, M. K., Wärnberg, F., Nilsson, G. P., & MacNeill, F. A. (2018) · British journal of surgery · doi:10.1002/bjs.10807 · Cited by 42
Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes
Cao, L., Sugumar, K., Keller, E., Li, P., Rock, L., Simpson, A. B., Freyvogel, M., Montero, A. J., Shenk, R., & Miller, M. E. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10459-3 · Cited by 41
Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer
Kantor, O., Wakeman, M., Weiss, A. C., Wong, S. M., Laws, A., Grossmith, S. C., Mittendorf, E. A., & King, T. A. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09073-6 · Cited by 41
Strategies for Increasing the Effectiveness of Aromatase Inhibitors in Locally Advanced Breast Cancer: An Evidence-Based Review on Current Options
Grizzi, G., Ghidini, M., Botticelli, A., Tomasello, G., Ghidini, A., Grossi, F., Fusco, N., Cabiddu, M., Savio, T., & Petrelli, F. (2020) · Cancer Management and Research · doi:10.2147/cmar.s202965 · Cited by 40
Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer
Kantor, O., Wong, S. M., Weiss, A. C., Metzger, O., Mittendorf, E. A., & King, T. A. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00177-6 · Cited by 38
Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma
Thornton, M., Williamson, H. V., Westbrook, K. E., Greenup, R. A., Plichta, J. K., Rosenberger, L. H., Gupta, A., Hyslop, T., Hwang, E. S., & Fayanju, O. M. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07564-9 · Cited by 38
Self-citation
Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer
Ding, Y., Ding, K., Qian, H., Yu, X., Zou, D., Yang, H., Mo, W., He, X., Zhang, F., Qin, C., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231895 · Cited by 38
Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak.
Viale, G., Licata, L., Sica, L., Zambelli, S., Zucchinelli, P., Rognone, A., Aldrighetti, D., Di Micco, R., Zuber, V., Pasetti, M., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0316 · Cited by 35
Neoadjuvant chemotherapy for luminal a breast cancer: Factors predictive of histopathologic response and oncologic outcome
Collins, P. M., Brennan, M. J., Elliott, J. A., Elwahab, S. M. A., Barry, K., Sweeney, K., Malone, C. M., Lowery, A., McLaughlin, R. P., & Kerin, M. J. (2020) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2020.11.053 · Cited by 36
Systemic Therapy in Breast Cancer
Corti, C., Batra-Sharma, H., Kelsten, M. F., Shatsky, R. A., Garrido-Castro, A. C., & Gradishar, W. J. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432442 · Cited by 37
The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness
de Oliveira, K. A., Sengupta, S., Yadav, A. K., & Clarke, R. C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1083048 · Cited by 32
Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer
Reinert, T., Gonçalves, R., & Ellis, M. J. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0538-9 · Cited by 32
FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort
Johnson, J. E., Choi, M. P., Dadmanesh, F., Han, B., Qu, Y., Yu-Rice, Y., Zhang, X., Bagaria, S. P., Taylor, C. R., Giuliano, A. E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12370 · Cited by 30
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives
Sirico, M., Virga, A., Conte, B., Urbini, M., Ulivi, P., Gianni, C., Merloni, F., Palleschi, M., Gasperoni, M., Curcio, A., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103900 · Cited by 33
COL11A1 serves as a biomarker for poor prognosis and correlates with immune infiltration in breast cancer
Luo, Q., Li, J., Su, X., Tan, Q., Zhou, F., & Xie, S. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.935860 · Cited by 29
Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer
Hyder, T., Bhattacharya, S., Gade, K., Nasrazadani, A., & Brufsky, A. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s273058 · Cited by 29
Exploration of prognosis and immunometabolism landscapes in ER+ breast cancer based on a novel lipid metabolism-related signature
Shen, L., Huang, H., Li, J., Chen, W., Yao, Y., Hu, J., Zhou, J., Huang, F., & Ni, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1199465 · Cited by 28
Time to surgery among women treated with neoadjuvant systemic therapy and upfront surgery for breast cancer
Prakash, I., Thomas, S. M., Greenup, R. A., Plichta, J. K., Rosenberger, L. H., Hyslop, T., & Fayanju, O. M. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-06012-7 · Cited by 28
Taking a Second Look at Neoadjuvant Endocrine Therapy for the Treatment of Early Stage Estrogen Receptor Positive Breast Cancer During the COVID-19 Outbreak
Thompson, C. K., Lee, M. K., Baker, J. L., Attai, D. J., & DiNome, M. L. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004027 · Cited by 27
Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer
Minami, C. A., Kantor, O., Weiss, A. C., Nakhlis, F., King, T. A., & Mittendorf, E. A. (2020) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2020.06.021 · Cited by 27
Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives
Varnier, R., Sajous, C., Talhouet, S. D., Smentek, C., Péron, J., You, B., Reverdy, T., & Freyer, G. (2021) · Cancers · doi:10.3390/cancers13194840 · Cited by 28
Over surgery in breast cancer
MacNeill, F. A., & Karakatsanis, A. (2016) · The Breast · doi:10.1016/j.breast.2016.10.023 · Cited by 27
Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis, such as the COVID-19 pandemic
Martí, C., & Sánchez-Méndez, J. I. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1027 · Cited by 26
Decision on Chemotherapy Amidst COVID-19 Pandemic: a Review and a Practical Approach from Iran
Rakhsha, A., Azghandi, S., & Taghizadeh‐Hesary, F. (2020) · Infection and Chemotherapy · doi:10.3947/ic.2020.52.4.496 · Cited by 26
How we Treat HR-Positive, HER2-Negative Early Breast Cancer
López‐Tarruella, S., Echavarría, I., Jerez, Y., Herrero, B., Casado, S. G., & Martín, M. (2022) · Future Oncology · doi:10.2217/fon-2021-0668 · Cited by 29
Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States
Pariser, A. C., Sedghi, T., Soulos, P. R., Killelea, B. K., Gross, C. P., & Mougalian, S. S. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05397-4 · Cited by 25
Management changes for patients with endocrine-related cancers in the COVID-19 pandemic
Raghavan, D., Tan, A. R., Story, E. S., Burgess, E. F., Musselwhite, L. W., Kim, E. S., & Clark, P. E. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0229 · Cited by 26
Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer
Sella, T., Gelber, S. I., Poorvu, P. D., Kim, H.-J., Dominici, L. S., Guzmán‐Arocho, Y. D., Collins, L. C., Ruddy, K. J., Tamimi, R. M., Peppercorn, J. M., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05989-5 · Cited by 25
Psychological Distress, Coping Strategies, and Quality of Life in Breast Cancer Patients Under Neoadjuvant Therapy: Protocol of a Systematic Review
Omari, M., Zarrouq, B., Amaadour, L., Benbrahim, Z., Asri, A. E., Mellas, N., Rhazi, K. E., Ragala, M. E. A., & Halim, K. (2022) · Cancer Control · doi:10.1177/10732748221074735 · Cited by 25
ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast
Agostinetto, E., Marta, G. N., Paesmans, M., Ameye, L., Veys, I., Buisseret, L., Neven, P., Taylor, D., Fontaine, C., Duhoux, F. P., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0358 · Cited by 25
Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Soliman, H. H., Wagner, S., Flake, D. D., Robson, M. E., Schwartzberg, L. S., Sharma, P., Magliocco, A. M., Kronenwett, R., Lancaster, J. M., Lanchbury, J. S. S., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-019-08039-7 · Cited by 25
Exploring the physiological role of the G protein-coupled estrogen receptor (GPER) and its associations with human diseases
Żabińska, M., Wiśniewska, K., Węgrzyn, G., & Pierzynowska, K. (2024) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2024.107070 · Cited by 24
Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer
Bischoff, H., Espié, M., & Petit, T. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01251-y · Cited by 27
Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
Lerebours, F., Pulido, M., Fourme, E., Debled, M., Becette, V., Bonnefoi, H. R., Rivera, S., MacGrogan, G. M., Mouret‐Reynier, M., de Lara, C. T., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0733-x · Cited by 23
Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
Lerebours, F., Cabel, L., & Pierga, J. (2021) · Cancers · doi:10.3390/cancers13040902 · Cited by 26
De-escalation of axillary irradiation for early breast cancer – Has the time come?
Senkus, E., Cardoso, M. J., Kaidar‐Person, O., Łacko, A., Meattini, I., & Poortmans, P. M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102297 · Cited by 24
Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study
Tang, L., Shu, X., & Tu, G. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02492-7 · Cited by 23
A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles
Gandhi, S., Brackstone, M., Hong, N. J. L., Grenier, D., Donovan, E. K., Lu, F., Skarpathiotakis, M., Lee, J., Boileau, J.-F., Perera, F. E., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06522-6 · Cited by 28
Molecular characterization of breast cancer needle core biopsy specimens by the 21‐gene Breast Recurrence Score test
Jakubowski, D. M., Bailey, H., Abran, J. M., Blacklock, A., Ciau, N. T., Mies, C., Tan, V. S., Young, R. L., Lau, A., & Baehner, F. L. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.26050 · Cited by 24
The role of quantitative estrogen receptor status in predicting tumor response at surgery in breast cancer patients treated with neoadjuvant chemotherapy
Raphael, J., Gandhi, S., Li, N., Lu, F., & Trudeau, M. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4269-6 · Cited by 22
Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis
Martín, M., Chacón, J. I., Antón, A., Plazaola, A., García-Martínez, E., Seguí, M. Á., Sánchez‐Rovira, P., Palacios, J., Calvo, L., Esteban, C., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0052 · Cited by 22
Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database
LeVasseur, N., Willemsma, K.-A., Li, H., Gondara, L., Yip, W., Illmann, C., Chia, S., & Simmons, C. E. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.05.020 · Cited by 21
Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer
Jia, Y., Song, Y., Dong, G., Hao, C., Zhao, W., Li, S., & Tong, Z. (2019) · Scientific Reports · doi:10.1038/s41598-019-49373-w · Cited by 21
The current landscape of aromatase inhibitors for the treatment of estrogen receptor-positive breast carcinoma
Bhutani, K., Vishwakarma, S., Yadav, P., & Yadav, M. K. (2025) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2025.106729 · Cited by 20
Updates on the treatment of invasive breast cancer: Quo Vadimus?
Nigdelis, M. P., Karamouzis, M. V., Kontos, M. C., Alexandrou, A. P., Goulis, D. G., & Lambrinoudaki, I. V. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.11.006 · Cited by 21
Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic
Spring, L. M., Specht, M. C., Jimenez, R., Isakoff, S. J., Wang, G. X., Ly, A., Shin, J. A., Bardia, A., & Moy, B. (2020) · New England Journal of Medicine · doi:10.1056/nejmcpc2002422 · Cited by 19
Self-citation
Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2− Breast Cancer: A Systematic Review and Meta-Analysis
Hong, K. M., Yao, L., Sheng, X., Ye, D., & Guo, Y. F. (2021) · Oncology Research and Treatment · doi:10.1159/000518573 · Cited by 19
Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
Garufi, G., Carbognin, L., Arcanà, C., Parola, S., Ventriglia, A., Doronzo, A., Garutti, M., Orlandi, A., Palazzo, A., Fabi, A., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102454 · Cited by 19

Authors: Spring, L. M., Gupta, A., Reynolds, K. L., Gadd, M. A., Ellisen, L. W., Isakoff, S. J., Moy, B., & Bardia, A.
Affiliations: Harvard University (US)
The University of Texas Southwestern Medical Center (US)
Corresponding author: Bardia, Aditya
ORCID: Spring, Laura M.
Gupta, Arjun
Reynolds, Kerry L.
Ellisen, Leif W.
Isakoff, Steven J.
Moy, Beverly
Bardia, Aditya
Venue: JAMA Oncology
Publisher: American Medical Association (AMA)
Published: 2016-11-01
Volume: 2
Issue: 11
Pages: 1477
ISSN: 2374-2437 (ISSN-L)
DOI: 10.1001/jamaoncol.2016.1897
PMC: PMC5738656
OpenAlex: W2467606258
Cited by: 396
References: 60
Citations by year: 2026: 28 · 2025: 52 · 2024: 48 · 2023: 36 · 2022: 48 · 2021: 56 · 2020: 63 · 2019: 26 · 2018: 13 · 2017: 18 · 2016: 8
FWCI: 9.03
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: JAMA Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (UL1TR001102)
National Cancer Institute (K12CA087723, T32CA071345)
National Center for Advancing Translational Sciences
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: neoadjuvant endocrine therapy, estrogen receptor-positive breast cancer, aromatase inhibitors, breast-conserving surgery, clinical response rate, combination chemotherapy, treatment toxicity, randomized controlled trials meta-analysis
MeSH terms: Breast Neoplasms, Female, Humans, Receptors, Estrogen, Randomized Controlled Trials as Topic, Treatment Outcome, Chemotherapy, Adjuvant, Antineoplastic Agents, Hormonal, Neoadjuvant Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer: A Systematic Review and Meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks